Caratterizzazione delle produzioni vitivinicole dell’area del Barolo: Un’esperienza pluridisciplinare triennale (4)

AIM. Wine yeast lees constitute a winemaking by-product that, unlike grape skins and seeds, are not sufficiently exploited to add value to the winemaking sector, as their treatment and disposal generally represents a cost for wineries [1].

The wine industry produces an enormous amount of waste every year. A wider inclusion of disregarded by-products in the human diet or its use as a source of bioactive compounds is a good strategy for reducing waste. It will not only introduce an added value to a waste product but also come upon the European Union and United Nations’ demands towards more sustainable agricultural approaches and circular economy.

Absinthe is historically described as a distilled, highly alcoholic beverage. It is an anise-flavoured spirit derived from botanicals, including the flowers and leaves of Artemisia absinthium L. (“grand wormwood”), together with green anise, sweet fennel, and other medicinal and culinary herbs.

Sterols are a fraction of the eukaryotic lipidome that is essential for the maintenance of the cell membrane integrity and their good functionality. During alcoholic fermentation, they ensure yeast growth, metabolism and viability, as well as resistance to osmotic stress and ethanol inhibition. Two sterol sources can support yeasts to adapt to fermentation stress conditions: ergosterol, produced by yeast in aerobic conditions, and phytosterols, plant sterols found in grape musts imported by yeasts in anaerobiosis. Little is known about the physiological impact of the assimilation of phytosterols in comparison to ergosterol and the influence of sterol type on fermentation kinetics parameters.

The French grapevine breeding program for durable resistance to downy and powdery mildew (INRAE-ResDur) was initiated more than 20 years ago to help reduce the heavy use of plant protection products and provide a durable mean to cope with a strong pathogen pressure. This program has now proved to be effective, with about ten new varieties already officially registered. However, there is still a lot to be done (1) to reduce the duration of each breeding cycle, (2) to diversify disease factors’ pyramiding and anticipate emerging diseases, (3) to work towards larger adoption of the new resistant varieties. New breeding schemes incorporating for example genomic prediction of breeding values are being evaluated to accelerate genetic gains, saving cost and time while handling complex traits.